aflibercept
Sensory organs (S01)US regulatory status: approved. Molecular target: Placenta growth factor.
- Target
- Placenta growth factor
- Mechanism
- Placenta growth factor inhibitor
biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO
CERo Therapeutics
CERO THERAPEUTICS HOLDINGS, INC.
CERo Therapeutics drug portfolio — 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
201 Haskins Way, 230, South San Francisco, California 94080, US HQ
17 Employees
Public company Type
CERO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 201 Haskins Way, 230, South San Francisco, California 94080, US
- Employees
- 17
- Programs
- 47
- Drugs
- 84
- Patents
- 14
CERo Therapeutics pipeline
Portfolio lens on 80 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CERo Therapeutics drug portfolio — 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
avelumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 other
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
binimetinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
-
brigatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- ALK tyrosine kinase receptor inhibitor
-
US regulatory status: approved.
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cemiplimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in CERo Therapeutics's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
choriogonadotropin alfa
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Molecular target: Lutropin-choriogonadotropic hormone receptor.
- Target
- Lutropin-choriogonadotropic hormone receptor
- Mechanism
- Luteinizing hormone/Choriogonadotropin receptor agonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in CERo Therapeutics's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
denosumab
Musculo-skeletal system (M05)US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 11.
- Target
- Tumor necrosis factor ligand superfamily member 11
- Mechanism
- Tumor necrosis factor ligand superfamily member 11 inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
encorafenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Serine/threonine-protein kinase B-raf.
- Target
- Serine/threonine-protein kinase B-raf
- Mechanism
- Serine/threonine-protein kinase B-raf inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
follitropin beta
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in CERo Therapeutics's portfolio. Molecular target: Follicle-stimulating hormone receptor.
- Target
- Follicle-stimulating hormone receptor
- Mechanism
- Follicle stimulating hormone receptor agonist
-
fruquintinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
ipilimumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
lorlatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- EML4-ALK inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to CERo Therapeutics in public FDA and regional records. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.
- Target
- Polyunsaturated fatty acid 5-lipoxygenase
- Mechanism
- Arachidonate 5-lipoxygenase inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
panitumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
pioglitazone
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in CERo Therapeutics's portfolio. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
ramucirumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor 2.
- Target
- Vascular endothelial growth factor receptor 2
- Mechanism
- Vascular endothelial growth factor receptor 2 inhibitor
-
US regulatory status: approved.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
sotorasib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: GTPase KRas.
- Target
- GTPase KRas
- Mechanism
- GTPase KRas inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha modulator
-
tarlatamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in CERo Therapeutics's portfolio. Molecular target: Delta-like protein 3.
- Target
- Delta-like protein 3
- Mechanism
- Delta-like protein 3 binding agent
-
temozolomide
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records. Molecular target: Hepatocyte growth factor receptor.
- Target
- Hepatocyte growth factor receptor
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.
-
topotecan
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in CERo Therapeutics's portfolio. Mechanism: DNA topoisomerase I, mitochondrial inhibitor.
- Mechanism
- DNA topoisomerase I, mitochondrial inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I, mitochondrial inhibitor
-
Development asset linked to CERo Therapeutics in public FDA and regional records.